Business
OncBioMune Receives Patent Protecting Novel Cancer Vaccine in Mexico
OncBioMune Receives Patent Protecting Novel Cancer Vaccine in Mexico.
About this update from Theralink Technologies Inc.
[{"type":"text","content":"\nOncBioMune Receives Patent Protecting Novel Cancer Vaccine in Mexico\n\nOncBioMune Receives Patent Protecting Novel Cancer Vaccine in Mexico\n\nBATON ROUGE, LA--(Marketwired - June 21, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) (\"OncBioMune\" or the \"Company\"), a revenue-stage biopharmaceutical company engaged in the development of targeted cancer therapies, a proprietary cancer vaccine technology and commercialization of a portfolio of products internationally, is pleased to report that that the Mexican Institute of Industrial Property has issued patent No. 343266, titled \"Composition and Method for Treating Cancer,\" protecting the intellectual rights of OncBioMune's ProscaVax throughout Mexico until January 8, 2032.ProscaVax is a clinical-stage protein therapeutic cancer vaccine combining tumor-associated antigens with biological adjuvants to selectively target tumor cells without damage to healthy cells. OncBioMune's intellectual property portfolio protecting ProscaVax and other technologies consists of 16 patents and patents pending spanning approximately 50 countries worldwide.\"This patent is particularly important given the Mexican markets are integral to our business model. We expect to announce the official commencement of our Phase 2/3 trial of ProscaVax for late-stage prostate cancer in Mexico any day now, so the timing of the new patent couldn't be any better,\" commented Andrew Kucharchuk, President and Chief Financial Officer at OncBioMune. \"An aging population and widespread adoption of screening for prostate specific antigen have Mexico facing a prostate cancer dilemma with little alternatives free of unpleasant side effects. We are optimistic that ProscaVax can provide a safe and effective solution to the nation's problem for years to come.\"Sign up for OncBioMune email alerts at: http://oncbiomune.com/email-alerts/. About OncBioMune Pharmaceuticals, Inc.OncBioMune Pharmaceuticals is a revenue-stage biopharmaceutical company engaged the development of novel cancer immunotherapy products, including a proprietary vaccine technology designed to stimulate the immune system to attack tumor cells without damaging healthy tissue. OncBioMune is also involved in drug development and commercialization internationally through our wholly-owned subsidiary, OncBioMune México, S.A. De C.V. Our lead pip...